Adeptus Health Inc Stock News

Shares of diagnostics and drug discovery concern Adaptive Biotechnologies Corporation have crashed over 90% as the commercial-stage concern struggles with profitability. On the top line, the company's

Andreas Halvorsen (Trades, Portfolio), the chief investment officer of Viking Global Investors, disclosed earlier this week he reduced his stake in Roivant Sciences Ltd. ( ROIV , Financial) by 14.73%.

Adaptive is awaiting an approval from the FDA on solid-tumor therapy afami-cel. The company uses a T-cell receptor platform to engineer cancer therapies.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

CrowdStrike, Prime Medicine, and Adaptive Biotechnologies were all on the Ark Invest shopping list on Thursday. CrowdStrike opened 8% lower on Thursday despite a "beat and raise" quarterly report.

UiPath, Prime Medicine, and Adaptive Biotechnologies were all on the Ark Invest shopping list on Thursday. Wood was particularly hungry for UiPath, adding shares of the robotics enterprise software sp

SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene

Medicine is not always simple. A drug that cures one patient can easily kill another, based on anything from their weight to their genes to anything else.

SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins -

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago.

Here is how Adaptive Biotechnologies (ADPT) and Avanos Medical (AVNS) have performed compared to their sector so far this year.

SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ge

The consensus price target hints at a 49.9% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e

Here is how Adaptive Biotechnologies (ADPT) and Geron (GERN) have performed compared to their sector so far this year.